Davita Target of Unusually High Options Trading (DVA)
Davita Inc (NYSE:DVA) was the recipient of unusually large options trading on Tuesday. Stock traders bought 42,540 call options on the stock. This is an increase of 1,660% compared to the average daily volume of 2,417 call options.
Large investors have recently added to or reduced their stakes in the company. Honkamp Krueger Financial Services Inc. acquired a new position in shares of Davita during the 3rd quarter worth about $143,000. Atlas Capital Advisors LLC boosted its position in shares of Davita by 247.9% in the 3rd quarter. Atlas Capital Advisors LLC now owns 2,592 shares of the company’s stock valued at $188,000 after purchasing an additional 1,847 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in shares of Davita in the 2nd quarter valued at about $206,000. Green Square Capital LLC acquired a new stake in shares of Davita in the 2nd quarter valued at about $208,000. Finally, IFG Advisory LLC acquired a new stake in shares of Davita in the 2nd quarter valued at about $213,000. 87.06% of the stock is owned by institutional investors and hedge funds.
NYSE:DVA opened at $58.69 on Wednesday. The stock has a market cap of $10.03 billion, a PE ratio of 17.68, a price-to-earnings-growth ratio of 0.80 and a beta of 1.09. Davita has a 1 year low of $54.38 and a 1 year high of $80.71. The company has a quick ratio of 1.82, a current ratio of 1.84 and a debt-to-equity ratio of 2.09.
Several research firms recently commented on DVA. Zacks Investment Research cut Davita from a “hold” rating to a “sell” rating in a research note on Tuesday, November 13th. TheStreet cut Davita from a “b-” rating to a “c+” rating in a research note on Thursday, November 8th. UBS Group began coverage on Davita in a research note on Thursday, November 15th. They set a “sell” rating and a $64.00 target price for the company. ValuEngine raised Davita from a “hold” rating to a “buy” rating in a research note on Tuesday, October 9th. Finally, Royal Bank of Canada boosted their target price on Davita from $70.00 to $78.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 8th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $82.44.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.